Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...

People with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders, even after successful ...

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

The Cardiac Dimensions Carillon Mitral Contour System is a minimally invasive mitral regurgitation therapy made possible by ...

People with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders, even after successful ...

People with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders, even after successful valve surgery. The condition is more common in women and younger patients ...

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...